Active Surveillance in Prostate Cancer
Active surveillance is an evidence-based management strategy for selected men with prostate cancer that appears unlikely to cause harm in the near future. Instead of treating immediately, the cancer is monitored with PSA tests, clinical review, prostate MRI and repeat biopsy when indicated. The purpose is to avoid or delay urinary and sexual side effects from surgery or radiation while still identifying higher-risk disease in time for curative treatment. Active surveillance is most established for Grade Group 1 disease and may be considered for carefully selected low-volume Grade Group 2 cancer. It is not the same as doing nothing, and it is not the same as watchful waiting.
Who is usually suitable?
The strongest candidates have low-risk disease: Grade Group 1, cancer apparently confined to the prostate, lower PSA and limited tumour volume. PSA density, MRI findings, number of positive biopsy cores, percentage involvement and family/genetic risk help refine suitability.
Selected men with favourable intermediate-risk disease, particularly small-volume Grade Group 2 with limited pattern 4 and otherwise reassuring features, may also discuss surveillance. The threshold for treatment is usually lower than in Grade Group 1.
Active surveillance vs watchful waiting
| Feature | Active surveillance | Watchful waiting |
|---|---|---|
| Goal | Delay or avoid treatment while preserving a curative window | Avoid burdensome cancer treatment when competing health risks are more important |
| Monitoring | Structured PSA, MRI and repeat biopsy as needed | Usually symptom-driven, less intensive testing |
| Typical patient | Lower-risk cancer with enough life expectancy to benefit from later cure if needed | Older/frailer patient or limited life expectancy |
| If cancer changes | Curative surgery or radiation may be offered | Treatment is mainly directed at symptoms and disease control |
What does surveillance involve?
- Regular PSA testing, with interval individualized to risk and previous results.
- Clinical review and assessment of urinary or new cancer-related symptoms.
- Repeat prostate MRI when appropriate, especially if PSA behaviour changes or previous imaging had a visible lesion.
- Confirmatory or repeat biopsy according to risk, MRI findings and local protocol.
- Reassessment of Grade Group and tumour volume after any new biopsy.
No single test can replace the others in every patient. PSA can fluctuate, MRI can miss some cancers, and biopsy samples only part of the prostate. Surveillance works by combining information over time.
What changes may trigger treatment?
- Upgrade to a higher Grade Group, especially a meaningful increase in Gleason pattern 4 or higher-grade disease.
- Increasing cancer volume on biopsy.
- MRI progression that is confirmed to be clinically important.
- PSA behaviour that raises concern and leads to confirmatory testing.
- Patient preference after informed discussion, even without formal progression.
A PSA rise by itself does not always mean surveillance has failed. It often triggers repeat PSA, MRI or biopsy before a treatment decision.
What are the benefits?
The major benefit is avoiding treatment side effects in men whose cancer may never require treatment. Many men remain on surveillance for years. Those who later show reclassification can move to surgery or radiation while treatment is still potentially curative.
What are the limitations?
- Anxiety from living with an untreated cancer diagnosis.
- Repeated blood tests, MRI scans and biopsies.
- Risk that biopsy or MRI initially underestimates higher-grade disease.
- Possibility of eventually needing treatment despite years of surveillance.
Does MRI replace repeat biopsy?
Not reliably in all patients. MRI is very useful for monitoring, but a stable MRI does not guarantee that histological grade is unchanged. Biopsy frequency can be individualized, but decisions should not rely on MRI alone when other features are concerning.
Lifestyle during active surveillance
No diet or supplement has been proven to make prostate cancer disappear. General cardiovascular health matters because many men with low-risk disease are more likely to be affected by heart or metabolic disease than by their prostate cancer. Maintain healthy weight, regular exercise, blood-pressure and diabetes control, and avoid smoking.
Moving from surveillance to treatment is not a failure
Active surveillance is designed to identify the minority of apparently favourable cancers that later show more concerning biology. A change in Grade Group, increasing amount of cancer on biopsy, convincing MRI progression or a concerning PSA pattern may prompt treatment. That transition means the surveillance programme has done its job; it does not mean the original decision to observe was wrong.
PSA alone should rarely trigger treatment without confirming what has changed. Infection, benign prostate growth and laboratory variation can alter PSA. MRI is very useful, but a stable MRI does not permanently replace tissue reassessment in all patients.
When to seek urgent medical care
Active surveillance itself is not an emergency situation. Seek urgent care for inability to pass urine, heavy visible bleeding with clots, fever with urinary symptoms, or new severe back pain accompanied by leg weakness, numbness or loss of bladder/bowel control. A PSA rise without these symptoms usually needs prompt review rather than an emergency-room visit.
Consultation checklist
- Initial and most recent biopsy reports.
- PSA values with dates.
- All prostate MRI reports and images.
- Prostate volume and PSA density.
- Family history and any germline genetic-test results.
- Baseline urinary and sexual function.
- A record of previous surveillance dates so missed tests can be identified.
FAQs
Is active surveillance safe?
For appropriately selected low-risk prostate cancer, long-term studies show very low rates of metastasis and prostate-cancer death when monitoring is performed properly.
Can the cancer suddenly become aggressive between visits?
Major biological change is usually not instantaneous, but initial sampling can underestimate disease. Structured follow-up is designed to detect meaningful reclassification early.
Does rising PSA automatically mean I need surgery?
No. PSA variation is common. A sustained or unexplained rise usually prompts reassessment with repeat PSA, MRI and/or biopsy.
Can Grade Group 2 be observed?
Selected low-volume Grade Group 2 cancers may be candidates, particularly when PSA density, MRI and the amount of pattern 4 are favourable. This requires more careful selection than Grade Group 1.
Can I switch from surveillance to treatment because I feel anxious?
Yes. Patient preference matters, but it is useful to discuss whether anxiety can be addressed without exposing you unnecessarily to treatment side effects.
Related reading
- Localized Prostate Cancer Explained
- Gleason Score Explained
- ISUP Grade Group Explained
- Prostate MRI Explained
- Radical Prostatectomy Explained
- Radiation vs Surgery for Prostate Cancer
- Active Surveillance for a Small Kidney Tumour
- Surveillance After Testicular Cancer Treatment
- Urologist in Latur
References
- European Association of Urology (EAU). EAU Guidelines on Prostate Cancer. 2026 edition https://uroweb.org/guidelines/prostate-cancer
- National Cancer Institute. Prostate Cancer Treatment (PDQ®)–Patient Version https://www.cancer.gov/types/prostate/patient/prostate-treatment-pdq
- Hamdy FC, Donovan JL, Lane JA, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med. 2023;388:1547-1558.
- American Urological Association/ASTRO. Clinically Localized Prostate Cancer Guideline (2022; amended 2026) https://www.auanet.org/guidelines-and-quality/guidelines/clinically-localized-prostate-cancer-aua/astro-guideline-2022